Cargando...
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms
The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explor...
Gardado en:
| Publicado en: | Cancer Chemother Pharmacol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6387687/ https://ncbi.nlm.nih.gov/pubmed/28488026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3323-8 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|